What is the recommended diagnostic and therapeutic approach for a patient with a common bile duct stricture?

Common Bile Duct Stricture: Diagnostic and Therapeutic Approach

For common bile duct strictures, endoscopic balloon dilation alone is the treatment of choice for dominant strictures, with endoscopic intervention preferred over percutaneous or surgical approaches to optimize quality of life and transplant-free survival.

Initial Diagnostic Evaluation

The diagnostic workup must first distinguish between benign and malignant etiologies, as 70% of biliary strictures in adults are malignant 1. Begin with:

• Cross-sectional imaging: MRI/MRCP is >95% sensitive and specific for detecting and localizing biliary strictures 2
• Stricture characterization: Define location (intrahepatic, hilar, or distal extrahepatic), extent (focal vs. diffuse), and whether singular or multifocal 1
• Tissue acquisition: When malignancy is suspected and ERCP-based sampling is nondiagnostic, EUS-guided sampling demonstrates superior sensitivity (89%) and accuracy (87%) compared to standard biliary brushing 3

Key Diagnostic Pitfall

Ultrasound has poor negative predictive value for biliary strictures despite being useful for screening ductal dilatation 2. Do not rely on ultrasound alone to exclude significant pathology.

Therapeutic Approach: Benign Strictures

Primary Treatment Strategy

Endoscopic intervention is strongly preferred over percutaneous or surgical approaches because it:

• Is less invasive and can be performed as outpatient procedure 4
• Provides better quality of life without external drains 4
• Can be repeated as necessary 4

Specific Treatment by Etiology

For dominant strictures (including PSC):

• Balloon dilation alone is recommended per European and American guidelines 4
• Stenting after dilation provides no added benefit and may increase adverse events, particularly cholangitis risk up to 50% 4
• If stenting is deemed necessary, short-term stenting (<2 weeks) shows 83% clinical/biochemical improvement with 80% remaining intervention-free at 1 year 4

For postcholecystectomy strictures:

• Multiple plastic stents (MPSs) are suggested as first-line 5
• Fully covered self-expandable metal stents (FCSEMS) can be considered when stricture is >2 cm distal from main hepatic confluence or for noncompliant patients 5

For chronic pancreatitis-related strictures:

• Temporary FCSEMS insertion for 6-12 months 5

Clinical Outcomes Data

Endoscopic dilation of dominant strictures achieves:

• Clinical and biochemical improvement in approximately 80% of noncirrhotic patients 4
• 5-year transplant-free survival of 81-94% (compared to 65-78% predicted by Mayo model) 4
• Potential reversal of secondary liver fibrosis 4

When to Use Percutaneous Approach

Reserve percutaneous transhepatic biliary drainage for:

• Failed endoscopic access 3
• Surgically altered anatomy precluding ERCP 3
• Hilar strictures requiring complementary drainage 5

Important caveat: ERCP-related adverse events are higher in PSC patients (7-18%) versus non-PSC patients (3-11%) due to disease complexity and prolonged procedures 4.

Therapeutic Approach: Malignant Strictures

Distal Malignant Strictures

• Endoscopic placement of 10-mm diameter SEMS is recommended for both preoperative and neoadjuvant biliary drainage 5
• Endoscopic drainage is preferred over surgical or percutaneous approaches for inoperable disease 5

Hilar Malignant Strictures

• ERCP is recommended over percutaneous transhepatic biliary drainage (PTBD) for preoperative drainage 5
• For Bismuth I-II: ERCP alone 5
• For Bismuth III-IV: ERCP or combination ERCP with EUS-guided biliary drainage (EUS-BD) is preferable over primary PTBD 5
• Target drainage of >50%, ideally ≥70% of viable nonatrophic liver volume 5

Failed or Unfeasible ERCP

EUS-BD is recommended over PTBD following failed ERCP 5:

• Use EUS-guided hepaticogastrostomy (EUS-HGS) when duodenal stricture present
• Use either EUS-HGS or EUS-guided choledochoduodenostomy when no duodenal stricture
• Reserve PTBD for when EUS-BD fails or is not feasible 5

Stent Selection Considerations

Plastic stents remain the mainstay for benign disease when stenting is required 4.

Avoid uncovered SEMSs (USEMSs) for unconfirmed etiology as they induce tissue hyperplasia with ingrowth and occlusion 4, 5.

Covered SEMSs: While theoretically attractive with larger diameters and removability, they carry increased stent migration risk and higher rates of cholecystitis and pancreatitis compared to plastic stents 4.

Multidisciplinary Management

Treat patients at tertiary centers with multidisciplinary teams to facilitate comprehensive care without jeopardizing future transplantation options 4. This is particularly critical since transplantation remains the only definitive treatment for progressive cholestatic diseases like PSC 4.